Supplementary materials

Supplementary methods

Oncomine database

The expression level of *SNHG20* in renal cancer and other types of cancers was analyzed using Oncomine Compendium of Expression Array data (<u>https://www.oncomine.org/resource/login.html</u>). Briefly, the *P* value for statistic significance was set up as 0.05, while the fold change was defined as all and the gene rank was defined as top 10%. The reporter ID and platform for datasets used in the current study were as follows: Gaedcke Colorectal, reporter ID, A_32_p8529, platform, Agilent Human Genome 44K; Hou Lung, reporter ID, 221621_at, platform, Human Genome U133 Plus 2.0 Array; TCGA Ovarian, reporter ID, 221621_at, platform, Human Genome U133A Array; Sanchez-Carbayo Bladder, reporter ID, 221621_at, platform, Human Genome U133A Array; Gumz Renal, reporter ID, 221621_at, platform, Human Genome U133A Array; Gumz Renal, reporter ID, 221621_at, platform, Human Genome U133A Array; Gumz Renal, reporter ID, 221621_at, platform, Human Genome U133A Array; Gumz Renal, reporter ID, 221621_at, platform, Human Genome U133A Array; Gumz Renal, reporter ID, 221621_at, platform, Human Genome U133A Array; Gumz Renal, reporter ID, 221621_at, platform, Human Genome U133A Array; Gumz Renal, reporter ID, 221621_at, platform, Human Genome U133A Array; Gumz Renal, reporter ID, 221621_at, platform, Human Genome U133A Array; Gumz Renal, reporter ID, 221621_at, platform, Human Genome U133A Array; Gumz Renal, reporter ID, 221621_at, platform, Human Genome U133A Array; Gumz Renal, reporter ID, 221621_at, platform, Human Genome U133A Array; Gumz Renal, reporter ID, 221621_at, platform, Human Genome U133A Array; Gumz Renal, reporter ID, 221621_at, platform, Human Genome U133A Array; Gumz Renal, reporter ID, 221621_at, platform, Human Genome U133A Array.

Supplementary Tables

Supplementary Table S1

Clinicopathological characteristics of 49 HCC patients (cohort 1)

Feature	N (%)	
Age(years)		
≤55	27 (55.1)	
>55	22 (44.9)	
Gender		
Male	45 (91.8)	
Female	4 (8.2)	
Tumor size (cm)		
≤ 5	17 (34.7)	
>5	32 (65.3)	
Edmondson Grade		
I-II	22 (44.9)	
III-IV	27 (55.1)	
BCLC stage		
А	27 (55.1)	
B+C+D	22 (44.9)	
Liver cirrhosis		
Yes	35 (71.4)	
No	14 (28.6)	
Portal vein tumor thrombus		
Yes	34 (69.4)	
No	15 (30.6)	
Metastasis		
Yes	4 (8.2)	
No	45 (91.8)	

Supplementary Table S2

Feature	N (%)
Age(years)	
≤55	84 (58.3)
>55	60 (41.7)
Gender	
Male	119 (82.6)
Female	25 (17.4)
Tumor size (cm)	
≤5	61 (42.4)
>5	83 (57.6)
Edmondson grade	
I-II	117 (81.3)
III-IV	27 (18.7)
BCLC stage	
A	91 (63.2)
B+C+D	53 (36.8)
Portal vein tumor thrombus	
No	122 (84.7)
Yes	22 (15.3)
Liver cirrhosis	
Yes	104 (72.2)
No	40 (27.8)
Metastasis	
Yes	6 (4.2)
No	138 (95.8)
Relapse	
Yes	45 (31.2)
No	99 (68.8)
No. tumor	. /
Solitary	106 (73.6)
Multiple	38 (26.4)

Clinicopathological characteristics of 144 HCC patients (cohort 2)

Supplementary Figure




Fig. S1 The expression level of *SNHG20* is up-regulated in colorectal cancer and other cancer types revealed by Oncomine analyses.

The box plots show that the expression level of *SNHG20* is up-regulated in rectal adenocarcinoma (A, P < 0.001), large cell lung cancer (B, P = 0.007), ovarian serous cystadenocarcinoma (C, P = 0.004), bladder cancer (D, P = 0.020), and clear cell renal cancer (E, P = 0.044).